Cemiplimab

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication used for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway. The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea. It was approved for medical use in the United States in September 2018, in the European Union in June 2019. and in Australia in July 2020. Cemiplimab is the first approval by the US Food and Drug Administration of a medication specifically for advanced cutaneous squamous cell carcinoma. Cemiplimab is a therapeutic alternative on the World Health Organization's List of Essential Medicines.

Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication used for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway. The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea. It was approved for medical use in the United States in September 2018, in the European Union in June 2019. and in Australia in July 2020. Cemiplimab is the first approval by the US Food and Drug Administration of a medication specifically for advanced cutaneous squamous cell carcinoma. Cemiplimab is a therapeutic alternative on the World Health Organization's List of Essential Medicines.

Mechanism of action

Cemiplimab targets the cellular pathway known as PD-1 (protein found on the body's immune cells and some cancer cells) so it acts as a checkpoint inhibitor.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1347863609 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

11 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.